Prophylaxis News and Research RSS Feed - Prophylaxis News and Research

Researchers find that same desire for intimacy is strong predictor for PrEp HIV prevention

Researchers find that same desire for intimacy is strong predictor for PrEp HIV prevention

Men in steady same-sex relationships where both partners are HIV negative will often forgo condoms out of a desire to preserve intimacy, even if they also have sex outside the relationship. [More]
First Edition: August 12, 2014

First Edition: August 12, 2014

Today's headlines include stories about how the federal government's experience with healthcare.gov has led to the creation of the U.S. Digital Service. [More]
Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share. [More]
Envarsus gets marketing authorization from EC for treatment of kidney and liver transplant patients

Envarsus gets marketing authorization from EC for treatment of kidney and liver transplant patients

Veloxis Pharmaceuticals A/S and Chiesi Farmaceutici S.p.A. today announced that the European Commission (EC) has granted marketing authorization for Envarsus for the prevention of organ rejection in adult kidney and liver transplant patients in the European Union. [More]
Continuous antibiotics for children with antenatal hydronephrosis not necessary, study finds

Continuous antibiotics for children with antenatal hydronephrosis not necessary, study finds

Up to 5 percent of all prenatal ultrasounds uncover antenatal hydronephrosis, or enlarged kidneys, the most commonly detected prenatal abnormality in the United States. Many children with this abnormality are treated continually with preventive antibiotics for the first few years of life with the hopes of preventing the condition's associated urinary tract infections. [More]
Lancet report: Support sex workers to prevent HIV

Lancet report: Support sex workers to prevent HIV

Across the world, in high- and low-income countries, women, men, and transgender people who sell sex are subjected to repressive and discriminatory law, policy, and practice, which in turn fuel human rights violations against them, including violence and discrimination. All of these factors are preventing sex workers from accessing the services which they need in order to effectively prevent and treat HIV infection, according to a major new Series on HIV and sex workers, published in The Lancet. [More]
New guidelines integrate biomedical advances and behavioral interventions for HIV people

New guidelines integrate biomedical advances and behavioral interventions for HIV people

In an innovative approach to HIV prevention, an interdisciplinary group of experts has come together for the first time to lay out a framework of best practices to optimize the role of the clinician in achieving an AIDS-free generation. [More]

Failure to provide adequate HIV services threatens global progress on HIV response, warns WHO

Failure to provide adequate HIV services for key groups - men who have sex with men, people in prison, people who inject drugs, sex workers and transgender people - threatens global progress on the HIV response, warns WHO. [More]
Cidara Therapeutics closes $32M Series A financing to advance novel echinocandin antifungal drug

Cidara Therapeutics closes $32M Series A financing to advance novel echinocandin antifungal drug

Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company's Cloudbreak™ targeted immunotherapy platform and biafungin™, a novel long acting echinocandin antifungal drug, into human clinical studies. [More]
Viewpoints: Working for benefits; fears for a pill to prevent HIV; possible Medicaid strategy for Virginia

Viewpoints: Working for benefits; fears for a pill to prevent HIV; possible Medicaid strategy for Virginia

[Economist Robert] Moffitt noted in an email that "the work incentives in the government safety net have greatly increased over the last 20 years: less welfare payments if you don't work, and much greater government payments if you do." [More]
State highlights: New La. abortion restrictions; new Mass. hospital deal; Medicare and ambulances in N.J.

State highlights: New La. abortion restrictions; new Mass. hospital deal; Medicare and ambulances in N.J.

A selection of health policy stories from Louisiana, Massachusetts, New Jersey, Wisconsin, Georgia, Missouri, Maryland, New York, Kansas and Washington state. [More]
Vitamin D with calcium can protect against risk of common bone fractures for seniors

Vitamin D with calcium can protect against risk of common bone fractures for seniors

For seniors over the age of 65, taking a daily supplement of vitamin D with calcium—but not vitamin D alone—can offer some protection against the risk of common bone fractures, according to an updated review from The Cochrane Library. [More]
Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, today announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva's array of biotechnology assets and capabilities. [More]
First Edition: June 3, 2014

First Edition: June 3, 2014

Today's headlines include coverage of Medicare data released Monday indicating that 2012 charges for some common inpatient hospital procedures dramatically increased over the previous year. [More]
Risk-based preventive measures lower frequency of postoperative blood clots

Risk-based preventive measures lower frequency of postoperative blood clots

Surgery patients are much less likely to get a blood clot in the lower extremities or lungs if they receive preventive treatment based on their individual clotting risk, in addition to walking soon after the operation. [More]
Patients with AIDS-related lymphomas may face increased risk of CNSi

Patients with AIDS-related lymphomas may face increased risk of CNSi

Patients with AIDS-related lymphomas (ARL) may face an increased risk of central nervous system involvement (CNSi) compared to other lymphomas. The effect of CNSi on survival outcomes, however, hasn't been thoroughly examined until now. [More]
Mylan launches generic version of GlaxoSmithKline's Malarone Tablets

Mylan launches generic version of GlaxoSmithKline's Malarone Tablets

Mylan Inc. today announced that it has launched Atovaquone and Proguanil Hydrochloride Tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline's Malarone® Tablets. [More]
Viewpoints: Political stand-off on insurance industry safeguards; VA's problems may lie in how government works

Viewpoints: Political stand-off on insurance industry safeguards; VA's problems may lie in how government works

The Obama administration calls it an adjustment, Republicans call it a bailout and insurance companies call it the one thing that might keep them from raising rates and angering policyholders. [More]
EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

Octapharma confirmed today the European Medicines Agency (EMA) has adopted a positive opinion towards human cell line recombinant human FVIII, Nuwiq®, recommending the granting of a marketing authorisation for the medicinal product for treatment and prophylaxis of bleeding (also during and after surgery) in paediatric and adult patients with haemophilia A (congenital FVIII deficiency). [More]
FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A. [More]